MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Soleno Therapeutics Market Cap 2011-2026 | SLNO
As of March 16, 2026 Soleno Therapeutics has a market cap of $ 1.72 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Soleno Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.08 B | 1.96 B | 803 M | 17.4 M | 1.89 M | 156 M | 110 M | 36.1 M | 15.6 M | 13.1 M | 12.6 M | 1.69 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.08 B | 1.69 M | 434 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
240 M | $ 13.71 | -0.22 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
608 M | $ 8.62 | 0.23 % | $ 574 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 155.46 | 1.83 % | $ 7.71 B | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 25.56 | 0.95 % | $ 710 M | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 17.01 | 3.4 % | $ 906 M | USA |
 |
DexCom
DXCM
|
25.5 B | $ 64.24 | -1.56 % | $ 25.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | $ 103.57 | 0.29 % | $ 19.5 B | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
467 M | $ 14.77 | 0.61 % | $ 447 M | USA |
 |
Guardant Health
GH
|
13.4 B | $ 85.49 | 1.75 % | $ 10.7 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
92.1 M | $ 17.88 | -6.63 % | $ 2.32 B | USA |
 |
Anixa Biosciences
ANIX
|
104 K | $ 2.83 | -1.05 % | $ 91.8 K | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 98.33 | 0.9 % | $ 8.11 B |  Irlanda |
 |
Danaher Corporation
DHR
|
150 B | $ 187.32 | 0.57 % | $ 134 B | USA |
 |
IQVIA Holdings
IQV
|
28.3 B | $ 164.72 | 1.1 % | $ 28.3 B | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
16.4 B | $ 118.94 | 2.92 % | $ 18.9 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 199.7 | -0.46 % | $ 22.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
42 B | $ 111.51 | -0.06 % | $ 33.9 B | USA |
 |
BioNano Genomics
BNGO
|
3.55 M | $ 1.11 | -0.89 % | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 9.0 | -0.99 % | $ 255 M | Israel |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 173.74 | 0.49 % | $ 24.2 B |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 9.09 | -2.78 % | $ 1.97 B | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
34.9 M | - | - | $ 79.8 M | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 450.41 | 1.48 % | $ 13 B | USA |
 |
National Research Corporation
NRC
|
315 M | $ 16.52 | 0.12 % | $ 370 M | USA |
 |
Celcuity
CELC
|
399 M | $ 114.22 | 3.11 % | $ 4.51 B | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 7.88 | -1.25 % | $ 1.01 B | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
OPKO Health
OPK
|
1.21 B | $ 1.19 | 2.59 % | $ 826 M | USA |
 |
Natera
NTRA
|
5.31 B | $ 187.85 | -1.29 % | $ 18.5 B | USA |
 |
Myriad Genetics
MYGN
|
409 M | $ 4.66 | -3.92 % | $ 432 M | USA |
 |
Pacific Biosciences of California
PACB
|
498 M | $ 1.33 | 4.72 % | $ 399 M | USA |